Medigus' 5-Year Follow Up of Pilot Study Published in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medigus' 5-Year Follow Up of Pilot Study Published in Surgical Endoscopy

OMER, Israel, April 14, 2015 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced the publication of a peer reviewed journal article of a study on the Medigus Ultrasonic Surgical Endostapler (MUSE(TM)), "Trans-oral anterior fundoplication: 5-year follow-up of pilot study" in the online edition of Surgical Endoscopy [1] , the official journal of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and European Association for Endoscopic Surgery (EAES).

According to the authors of the study, the results demonstrate a durable positive impact on the patients treated with MUSE in terms of reduction- or elimination- of GERD medication use and improvement in GERD-HRQL (Health Related Quality of Life) over the long-term. The research indicates that fundoplication performed with MUSE has the potential to effectively relieve GERD similar to results from more invasive, laparoscopic procedures.

The study evaluated 13 GERD patients who had incomplete response to high dose proton pump inhibitors (PPI) - the most effective class of GERD medications. The patients underwent trans-oral anterior partial fundoplication for the treatment of GERD with the MUSE system.  At six weeks, it was reported that 92% of patients had stopped GERD medications daily and had normalized quality of life scores, 69% had eliminated use of GERD medications altogether and average esophageal acid content was significantly reduced following the procedure. Based on these outcomes, the study authors concluded that the procedure was an effective treatment choice for GERD and initiated a larger, multicenter  study. Meanwhile, the researchers continued to interview these 13 patients annually. After 5 years, over 90% of study participants maintained their normalized quality of life measures and approximately 77% had ceased taking daily GERD medications.

The procedure performed with the MUSE system is incisionless and leverages recent technological advancements in microvisualization, ultrasound and surgical stapling, to deliver an innovative solution for those who suffer from GERD.  With MUSE, a single physician or surgeon is able to provide the treatment, and because no incisions are required, it has the potential to offer enhanced patient comfort, reduced hospital stays and post-procedure recovery times over more invasive, laparoscopic procedures.

"We are pleased that Surgical Endoscopy has recognized and published these study results, as it further supports MUSE's potential to be a leading endoscopic solution for the long-term treatment of GERD. The completion of this IRB-approved study and publication of its results is another achievement for Medigus, as the use of MUSE continues to grow in countries around the world," said Chris Rowland, CEO of Medigus.

The publication of this pilot study is the first long-term follow-up available for the MUSE system. This pilot study was a precursor to a much larger pivotal study, which was recently published. "Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE(TM)) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial," was published in the January 2015 issue of Surgical Endoscopy.

About GERD
Gastroesophageal reflux disease (GERD) occurs when the lower esophageal sphincter spontaneously opens or does not properly close after use, thereby allowing for stomach contents to rise into the esophagus, causing heartburn, irritation and potentially other discomforts. It affects approximately 24M Americans each year; 14.5M adults experience GERD symptoms at least twice a week, and 2.4M adults experience severe symptoms. While some patients can attain symptom relief through the use of proton pump inhibiters, or PPIs, (acid reducing medications), there is, however, growing concern around the prolonged chronic use of PPIs, including increased risk of bone fracture, infectious complications, and interference with anti-platelet medication and the adsorption of essential vitamins and minerals. A persistent state of untreatable GERD could potentially lead to Barrett's esophagus, a precancerous state which can lead to esophageal cancer. Patients who suffer from daily GERD are more likely to develop esophageal cancer.

About MUSE

The MUSE system is a leading technology in Natural Orifice Endoscopic
Surgery procedures. The single operator system performs anterior partial fundoplication with standard surgical staples in a less invasive way, compared to other surgical procedures. Its intuitive endosurgical platform consists of a single use flexible surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder. The endostapler, which resembles an endoscope, is designed to be operated by a single user, includes a handle with controls, an 80cm flexible shaft, a 5cm rigid section holding a cartridge with 5 standard 4.8mm titanium surgical staples, a ratchet controlled one-way articulating section, and a distal tip.  The MUSE system is FDA cleared and CE marked. Medigus anticipates that the new Category 1 Current Procedural Terminology (CPT®) code, recently created by The American Medical Association (AMA) for Esophagogastric Fundoplasty Trans-Orifice Approach procedures, would be the code used for MUSE.

About Medigus
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. Medigus is a pioneer developer of a unique proprietary endoscopic device, the MUSE(TM) system, to treat gastroesophageal reflux disease (GERD), one of the most common chronic diseases in the western world. As an expert in micro-endoscopic devices, Medigus has developed a range of micro CMOS (complementary metal-oxide semiconductor) and CCD (charge-coupled device) video cameras, including micro ScoutCam(TM) 1.2, which to the best of the company's knowledge, is the smallest in the world. These innovative cameras are suitable for both medical and industrial applications. The MUSE system incorporates Medigus' revolutionary micro ScoutCam technology. Based on its proprietary technologies, Medigus designs and manufactures endoscopy and micro camera systems for partner companies, including major players in the medical and industrial fields. The company is committed to providing integrated solutions to meet all of its customer's imaging needs. Medigus is traded on the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.microscoutcam.com .

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. Forward-Looking Statements involve uncertainties which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Among the factors which may cause the actual results to differ from the Forward-Looking Statements are changes in the target market and the introduction of competitive products, regulatory, legislative and policy changes, and clinical results. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.

###

MEDIA CONTACT:
Chantal Beaudry/ Carrie Yamond
Lazar Partners Ltd.
212-867-1762
cbeaudry@lazarpartners.com
cyamond@lazarpartners.com

INVESTOR RELATIONS:
Miri Segal-Scharia
Hayden/ MS-IR LLC
917-607-8654
msegal@ms-ir.com

[1] Roy-Shapira, A., Bapaye A., Date, S., Pujari, R., & Dorwat, S. (2015). Trans-oral anterior fundoplication: 5-year follow-up of pilot study. Surgical Endoscopy, online February 19, 2015 doi:# 10.1007/s00464-015-4142-9
http://link.springer.com/article/10.1007%2Fs00464-015-4142-9

HUG#1910841

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 29

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 62

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 431

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Kennedy Funding Secures $2.85M Loan for Innovative Project

Updated Category News Views 187

Kennedy Funding Closes Major Land Loan for Development Leading private lender, Kennedy Funding, has successfully finalized a significant loan amounting to $2.85 million. This financing supports an exciting mixed-use development project that aims to enhance urban living through the addition of residential units and commercial spaces. Details of the Loan Agreement Secured...

Continue Reading
Expert Opinions on Tesla's Recent Vehicle Pricing Strategy

Updated Category News Views 340

Insightful Perspectives on Tesla's Pricing Changes In the dynamic world of electric vehicles, significant voices like Ross Gerber and Gary Black are raising concerns about Tesla Inc. (NASDAQ: TSLA) and its latest pricing strategy for its affordable Model Y and Model 3 trims. These experts have directed their criticism at Tesla following the company's decision to introduce...

Continue Reading
Analyzing Progress and Challenges in America's New Era

Updated Category News Views 259

Progress and Prosperity in America's New Era The past few months have been quite pivotal for the United States as tremendous advancements unfold under the current administration. The focus this week centers around the concept of progress, showcasing the concrete steps made toward economic stability and increased job opportunities. These developments draw attention to the...

Continue Reading
Lithia & Driveway Anticipates Strong Q1 2025 Earnings Report

Updated Category News Views 240

Lithia & Driveway Anticipates Strong Q1 2025 Earnings Report Lithia & Driveway (NYSE: LAD) is preparing to unveil its first quarter financial results for 2025. The company has announced that these results will be available before the market opens, allowing stakeholders and investors to evaluate the performance of the automotive retailer. Key Date for Earnings Release The...

Continue Reading
Hargreave Hale VCT's Recent Share Purchase Explained

Updated Category News Views 118

Correction on Share Purchase Announcement There has been a clarification regarding a previous announcement from Hargreave Hale AIM VCT PLC concerning a recent transaction in their own shares. Initially made public with an incorrect headline, the announcement aims to ensure all shareholders are accurately informed about the company's activities. Details of Share Purchase...

Continue Reading